ERS Genomics announced today that the U.S. Patent and Trademark Office
(USPTO) has granted Dr. Emmanuelle Charpentier, ERS Genomics’
co-founder, together with the University of California and University of
Vienna, their first U.S. patent with claims covering the use of
CRISPR/Cas9 technology for gene editing. The patent covers the use of an
optimized guide RNA format in all environments including human cells.
The USPTO deemed the claims in this patent unrelated to the ongoing
interference appeal between the Charpentier/UC/Vienna group and the
Broad Institute/MIT/Harvard group.
“We are very pleased to finally see the first of what we expect to be
many more U.S. patents issued from the seminal discoveries of Emmanuelle
Charpentier and Jennifer Doudna and their research teams. The USPTO
deemed the claims allowable despite efforts by lawyers representing the
Broad Institute to block the issuance of the patent, leading to today’s
formal grant,” commented Eric Rhodes, CEO of ERS Genomics.
“Since we have been waiting quite some time for our patents to issue in
the United States, it is gratifying to see the formal rights be granted
to apply this promising technology for the benefit of health and
medicine,” commented Dr. Emmanuelle Charpentier, one of the principal
inventors on the patent.
“There seems to be popular recognition within the scientific community
of the ground-breaking nature of the Charpentier/Doudna discovery, but
it has been somewhat frustrating to have waited so long to see that
being translated into appropriate patent recognition in the U.S.,”
continued Rhodes. “Despite having filed more than six months later than
Drs. Charpentier and Doudna, the Broad Institute had their patents
issued early because they paid special fees to have their patent review
expedited. This has led to further confusion among those groups looking
to secure appropriate license to use the technology.”
The CRISPR/Cas9 patent has been filed broadly throughout the world and
has already been granted in over 45 countries, including throughout the
EU, Japan and in China.
About ERS GenomicsERS Genomics was formed to provide broad
access to the foundational CRISPR-Cas9 intellectual property held by Dr.
Emmanuelle Charpentier. Non-exclusive licenses are available for
research and sale of products and services across multiple fields
including: research tools, kits, reagents; discovery of novel targets
for therapeutic intervention; cell lines for discovery and screening of
novel drug candidates; GMP production of healthcare products; livestock;
production of industrial materials such as enzymes, biofuels and
chemicals; and synthetic biology. For additional information please
View source version on businesswire.com: https://www.businesswire.com/news/home/20180619005241/en/